Using AI to predict life expectancy—and identify candidates for experimental trials—among glioblastoma patients

| February 27, 2020
glioblastoma exlarge
Credit: CNN
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Glioblastoma is an aggressive, killer disease. While victims of this fast-moving brain tumor comprise only about 15% of all people with brain cancer, its victims rarely survive more than a few years after diagnosis.

[R]esearchers used the tools of Artificial Intelligence (AI)–in this case, computer image analysis of the initial MRI scans taken of brain cancer patients–and compared that image analysis with genomic research to analyze the cancer.

The result: A new and more accurate way to not only determine the relative life expectancy of glioblastoma victims–but identify who could be candidates for experimental clinical drug trials, said [researcher] Pallavi Tiwari.

Related article:  Exploring the maleness of autism and how it shapes the empathy of autistic people

The AI model used by the researchers leveraged features from the region adjacent to the tumor, as well as inside the tumor to identify which patients had a poor prognosis, Pallavi said. Then, they used gene-expression information to shed light on which biological pathways were associated with those images.

“Our results demonstrated that image features associated with poor prognosis were also linked with pathways that contribute to chemo-resistance in glioblastoma. This could have huge implications in designing personalized treatment decisions in glioblastoma patients, down the road.” she said.

Read the original post

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend